Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Rating of “Moderate Buy” by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $277.8889.

A number of equities research analysts have commented on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. The Goldman Sachs Group raised their price objective on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. TD Cowen restated a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Bank of America increased their target price on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Finally, Citigroup lifted their price target on shares of Krystal Biotech from $320.00 to $336.00 and gave the company a “buy” rating in a research report on Monday, January 12th.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $272.61 on Thursday. The company has a market capitalization of $7.91 billion, a P/E ratio of 40.87 and a beta of 0.49. The company has a 50 day simple moving average of $258.03 and a 200-day simple moving average of $202.68. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $295.98.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the sale, the insider owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Soleus Capital Management L.P. raised its holdings in shares of Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after buying an additional 481,200 shares during the period. Braidwell LP grew its position in Krystal Biotech by 81.6% in the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after acquiring an additional 327,067 shares in the last quarter. Norges Bank acquired a new position in Krystal Biotech in the 2nd quarter valued at about $38,861,000. William Blair Investment Management LLC increased its stake in Krystal Biotech by 152.1% during the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after purchasing an additional 227,038 shares during the period. Finally, First Trust Advisors LP lifted its position in shares of Krystal Biotech by 571.3% during the second quarter. First Trust Advisors LP now owns 222,370 shares of the company’s stock worth $30,567,000 after purchasing an additional 189,245 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.